China's pharmaceutical industry faces challenges in realizing capital and asset value, and ushers in new opportunities
In recent years, under the influence of policies, markets and capital, China's pharmaceutical industry has experienced rapid development and profound changes. However, with the intensification of industry competition and the changes in the macroeconomic environment, pharmaceutical companies are facing challenges in financial pressure and realizing asset value. At the same time, new opportunities such as innovative drugs, digital medical care and internationalization have also brought new growth points to the industry. This article will explore the current status and future trends of the pharmaceutical industry through structured data and analysis.
1. Funding pressure: The financing environment tightens, and R&D investment faces challenges
According to public data in the past 10 days, the scale and frequency of financing in the pharmaceutical industry have declined, especially innovative drug companies in the early stages are facing great pressure. The following is the statistics on the financing of the pharmaceutical industry in the second quarter of 2024:
| Financing phase | Number of financing cases | Average financing amount (billion yuan) | Year-on-year changes |
|---|---|---|---|
| Seed wheel/angel wheel | 15 | 0.8 | -35% |
| Round A | twenty two | 2.5 | -28% |
| Round B and above | 18 | 5.2 | -15% |
| IPO | 5 | 12.0 | -40% |
It can be seen from the table that the scale of financing and the number of cases in the pharmaceutical industry at all stages are showing a downward trend, especially the IPO market has cooled down significantly. This reflects that the capital market's valuation logic for the pharmaceutical industry is being adjusted, and investors are paying more attention to the profitability and commercialization prospects of companies.
2. Achievement of asset value: active mergers and acquisitions, but differentiated valuations
Under financial pressure, pharmaceutical companies are realizing asset value through asset sales, mergers and acquisitions and restructuring. The following are the key data of recent mergers and acquisitions in the pharmaceutical industry:
| Transaction Type | Number of transactions | Average transaction amount (billion yuan) | Main fields |
|---|---|---|---|
| Innovative drug assets | 8 | 6.5 | Tumor, self-immunization |
| CXO Integration | 5 | 4.2 | CDMO, clinical CRO |
| Transformation of traditional pharmaceutical companies | 7 | 3.8 | Traditional Chinese medicine, chemical medicine |
Data shows that innovative drug assets are still a hot spot in the M&A market, but the valuation has declined significantly from the peak period from 2021 to 2022. At the same time, the acceleration of integration of the CXO (pharmaceutical outsourcing service) industry reflects the trend of increasing industry concentration.
3. New Opportunities: Innovation, Digitalization and Internationalization
Despite the challenges, the Chinese pharmaceutical industry still shows strong growth potential in emerging areas:
| field | Market size (2024 estimate, 100 million yuan) | Annual growth rate | Representative of the enterprise |
|---|---|---|---|
| ADC (antibody-conjugated drug) | 150 | 45% | Rongchang Biology, Hengrui Medicine |
| Gene therapy | 80 | 60% | Innovent Biologics, Boya Jiyin |
| Digital Therapy | 30 | 55% | Doctor Wechat, Good Doctor Ping An |
It can be seen from the data that cutting-edge technology fields such as ADC and gene therapy have maintained rapid growth, and digital medical care has also become a new trend in the industry. In addition, the internationalization process of Chinese pharmaceutical companies has accelerated. In the first half of 2024, 12 domestic innovative drugs have been approved by the FDA or EMA, setting a record high.
4. Policy support and industry prospects
Recently, the National Health Insurance Administration and the Drug Administration have successively issued policies to optimize the pricing and approval process of innovative drugs. For example,"Simple Renewal" RulesThe launch of the company is expected to reduce the price reduction of innovative drugs after entering medical insurance and stabilize corporate expectations. At the same time, biopharmaceutical industry funds have been established in Beijing, Shanghai and other places to alleviate the financial pressure of enterprises.
Looking ahead, China's pharmaceutical industry will enter"High-quality innovation"stage. Companies with the following characteristics are expected to stand out: 1) Differentiated R&D pipelines; 2) Efficient commercialization capabilities; 3) Global layout. An industry reshuffle is inevitable, but real innovators will gain greater room for development.
Overall, China's pharmaceutical industry is in a critical period of transformation. Although the financial pressure is difficult to alleviate in the short term, with the optimization of the policy environment and technological breakthroughs, the long-term trend of the industry has not changed. Enterprises need to actively adjust their strategies and seize the new opportunities brought by innovation and internationalization.
check the details
check the details
en
